GlassScriptPhysician profile
Brandi Rolling Thomas
NPI 1184244402
$1,135.53
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $596 · 2022: $158 · 2023: $363 · 2024: $18.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $213.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $193.06 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $97.08 | 2023 | Rexulti |
| Abbvie INC. | $83.96 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $81.24 | 2022-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $77.82 | 2021-2023 | Trintellix |
| Alkermes, INC. | $53.55 | 2022-2023 | Aristada, Lybalvi |
| Optinose US, INC. | $50.68 | 2021 | |
| Amgen INC. | $49.84 | 2021-2024 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $43.12 | 2023 | Austedo |
| Uswm, LLC | $38.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.98 | 2022-2023 | Spravato |
| Tersera Therapeutics LLC | $29.49 | 2021 | |
| Lundbeck LLC | $24.38 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $18.95 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $17.69 | 2023 | Qelbree |
| Pharming Healthcare, INC. | $14.08 | 2021 | |
| Kaleo, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.